Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial.

Karine LacombeThomas HuesoRaphael PorcherArsene MekinianThibault ChiarabiniSophie Georgin-LavialleFlorence AderJulien SaisonGuillaume Martin-BlondelNathalie De CastroFabrice BonnetCharles CazanaveAnne FrancoisPascal MorelOlivier HermineValerie PourcherMarc MichelXavier LescureNora SoussiPhillipe BrunFanny PommeretPierre SellierStella RoussetLionel PirothJean-Marie MichotGabriel BaronXavier de LamballerieXavier MariettePierre-Louis TharauxMatthieu Resche-RigonPhilippe RavaudTabassome SimonPierre Tiberghien

Published in: BMJ medicine (2023)

ClinicalTrials.gov NCT04345991.

Keyphrases

open label
clinical trial
coronavirus disease
sars cov
phase ii
study protocol
phase iii
double blind
phase ii study
healthcare
respiratory syndrome coronavirus
randomized controlled trial
adverse drug
squamous cell carcinoma
locally advanced